Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.84 -1.2%	$47.09	$42.96 ▼ $63.33	$97.38B	0.36	13.26 million shs	11.60 million shs
GPH Graphite One	C$0.81 -4.7%	C$0.84	C$0.64 ▼ C$1.14	C$82.02M	1.02	98,893 shs	622,300 shs
OGN Organon & Co.	$9.42 +1.5%	$9.69	$8.01 ▼ $23.10	$2.45B	0.6	4.49 million shs	3.55 million shs
PHAR Pharming Group	$13.70 +8.2%	$10.93	$6.73 ▼ $17.08	$938.59M	0.02	6,238 shs	19,253 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.28%	+1.08%	+0.68%	+3.20%	-0.12%
GPH Graphite One	+2.41%	-13.27%	-16.67%	+8.97%	+6.25%
OGN Organon & Co.	-1.03%	-1.17%	-5.41%	+6.73%	-55.90%
PHAR Pharming Group	+3.60%	+11.25%	+26.08%	+21.44%	+54.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.7874 of 5 stars	2.1	5.0	4.2	4.0	3.3	2.5	1.3
GPH Graphite One	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	4.7554 of 5 stars	3.3	2.0	1.7	3.7	3.7	1.7	2.5
PHAR Pharming Group	2.0036 of 5 stars	3.5	3.0	0.0	0.0	1.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.24	Hold	$56.38	17.84% Upside
GPH Graphite One	0.00	N/A	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.08% Upside
PHAR Pharming Group	3.00	Buy	$30.00	118.98% Upside

Current Analyst Ratings Breakdown

Latest PHAR, OGN, BMY, and GPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/1/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $47.00
7/31/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	2.02	$5.83 per share	8.20	$8.59 per share	5.57
GPH Graphite One	N/A	N/A	C$0.01 per share	94.17	C$0.44 per share	N/A
OGN Organon & Co.	$6.40B	0.38	$4.96 per share	1.90	$2.82 per share	3.34
PHAR Pharming Group	$297.20M	3.16	$0.08 per share	164.85	$3.50 per share	3.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.29	7.86	2.47	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
GPH Graphite One	-C$4.90M	-C$0.07	N/A	∞	N/A	N/A	-10.96%	-6.61%	N/A
OGN Organon & Co.	$864M	$2.69	3.50	2.52	0.98	11.15%	163.88%	6.99%	10/30/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	456.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)

Latest PHAR, OGN, BMY, and GPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.18%	N/A	100.00%	17 Years
GPH Graphite One	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Latest PHAR, OGN, BMY, and GPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.54	1.21	1.11
GPH Graphite One	0.02	1.09	0.33
OGN Organon & Co.	11.98	1.65	1.13
PHAR Pharming Group	0.38	2.79	2.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GPH Graphite One	0.07%
OGN Organon & Co.	77.43%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
GPH Graphite One	28.81%
OGN Organon & Co.	1.96%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GPH Graphite One	20	101.25 million	N/A	Not Optionable
OGN Organon & Co.	4,000	259.97 million	254.87 million	Not Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable

PHAR, OGN, BMY, and GPH Headlines

Recent News About These Companies

Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?

August 22 at 10:55 AM | zacks.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest

August 17, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?

August 16, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy?

August 13, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

August 12, 2025 | marketbeat.com

Pharming Group NV (PHARMA.XD) - Yahoo Finance

August 10, 2025 | finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Hits New 1-Year High - Still a Buy?

August 7, 2025 | marketbeat.com

Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet

August 6, 2025 | zacks.com

Pharming Group (NASDAQ:PHAR) Trading Up 7.9% - Should You Buy?

August 5, 2025 | marketbeat.com

Pharming Group N.V. Reports Strong Q2 Earnings

August 4, 2025 | theglobeandmail.com

Pharming Group to participate in August investor conference

August 4, 2025 | uk.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume Following Better-Than-Expected Earnings

August 2, 2025 | marketbeat.com

Pharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)

August 2, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up After Better-Than-Expected Earnings

August 1, 2025 | marketbeat.com

New Strong Buy Stocks for August 1st

August 1, 2025 | zacks.com

Pharming Group reports second quarter and first half 2025 financial results and provides business update

July 31, 2025 | finance.yahoo.com

High Growth Tech Stocks To Watch In Europe July 2025

July 29, 2025 | finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Still a Buy?

July 26, 2025 | marketbeat.com

Best Momentum Stocks to Buy for July 25th

July 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, OGN, BMY, and GPH Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.84 -0.59 (-1.21%)

Closing price 03:59 PM Eastern

Extended Trading

$47.94 +0.10 (+0.20%)

As of 07:12 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Graphite One CVE:GPH

C$0.81 -0.04 (-4.71%)

As of 03:57 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Organon & Co. NYSE:OGN

$9.42 +0.14 (+1.51%)

Closing price 03:59 PM Eastern

Extended Trading

$9.44 +0.02 (+0.16%)

As of 05:06 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Pharming Group NASDAQ:PHAR

$13.70 +1.04 (+8.21%)

Closing price 03:52 PM Eastern

Extended Trading

$13.27 -0.43 (-3.14%)

As of 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time